EGFR is epidermal growth factor receptor, EGFR mutation, is related to tumor proliferation.EGFR mutation is mainly treated by targeted drugs.
1. At present, the commonly used EGFR-targeted drugs are divided into three generations: first generation: gefitinib, erlotinib, ectinib; second generation: afatinib, daclatinib; third generation: ositinib, amitinib.
2. First-generation targeted drugs can cause diarrhea and skin rash, so people with related symptoms are not recommended to use first-generation targeted drugs. The second generation of targeted drugs have more adverse reactions. The third generation of targeted drugs has a small molecular structure, is more sensitive to EGFR, and has fewer adverse reactions. Patients should choose the drugs according to their own situation under the guidance of doctors.
3. For patients with brain metastasis, the clinic usually chooses the third generation of EGFR-targeted drugs for treatment, and for those with rare mutations in EGFR, the clinic usually chooses the second generation of targeted drugs for treatment.
Patients can prevent EGFR mutations by strengthening exercise, enhancing their immunity and improving their daily life.